Imagen de Portada
Código QR

First-in-class glaucoma therapy shows promise in 28-day phase II study.

Publicado en:Ophthalmology Times Vol. 40; no. 2; pp. 29 - 31
Autores principales: Guttman Krader, Cheryl, Bacharach, Jason
Formato: pictorial Journal Article
Publicado: MJH Life Sciences Feb2015
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=100887945&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 100887945
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        0193032X
        OTI
      jtl: Ophthalmology Times
      issn: 0193032X
      maglogo: N
    pubinfo:
      dt: Feb2015
      vid: 40
      iid: 2
      pid: 54670
      pub: MJH Life Sciences
      place: Cranbury, New Jersey
    artinfo:
      ui:
        100887945
        100887945
        107772728
        100887945
      ppf: 29
      ppct: 2
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: First-in-class glaucoma therapy shows promise in 28-day phase II study.
      aug:
        au:
          Guttman Krader, Cheryl
          Bacharach, Jason
        affil: Consultant, Aerie Pharmaceuticals
      sug:
        subj:
          Glaucoma Drug Therapy
          Intraocular Pressure Drug Effects
          Research
      pubtype: Trade Publication
      doctype:
        pictorial
        Journal Article
      ougenre: Article
      ab:
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N